HtmlToText
home about mission team contact access to new treatments in advanced cancers and severe inflammatory diseases about us inatherys is a biotechnology company developing monoclonal antibodies for therapies these innovative molecules are dedicated to the treatment of advanced cancers without therapeutic alternative ina01 and new generations of antibodies are targeting the transferrin receptor (cd71). cd71 regulates cellular activation and proliferation . preclinical studies have shown that tumor cells , with high proliferative capacity, strongly express the cd71 receptor. therefore antibody against cd71 will preferentially target cancer cells. severe inflammatory diseases resistant to conventional treatment ina02 is an anti-cd89 antibody . the cd89 receptor is expressed on the surface of many cells involved in inflammation . indeed ina02 takes effect prior to the inflammatory reaction in the body. ina02 binds itself onto cd89 receptor expressed only by inflammatory cells and reduces the release of the mediators responsible for the inflammation. inatherys, a biotechnology company from academic research inatherys, a biotechnology company from academic research. founded in 2009, inatherys is a biotechnology company spin-off from inserm (institut national de la santé et de la recherche médicale). the founders come from academic research units. inserm u1149 – renal immunopathology, bichat hospital, paris imagine institute – laboratory of molecular mechanisms of hematologic disorders in partnership with adult hematology department of necker hospital , paris a highly complementary and experienced team inatherys' strength lies in the engagement of a team of researchers, onco/hematology physicians, entrepreneurs and pharmaceutical development specialists. our medical, scientific and monoclonal antibodies development expertises, performed for more than 20 years, is recognized at the international stage . our mission cancers and severe inflammatory diseases: a public health issue every year, 12 million people are affected by cancers in the world. severe inflammatory diseases handicap hundreds of millions of people. inatherys' mission is to design and develop innovative molecules providing solutions for the treatment of advanced cancers without therapeutic alternative severe inflammatory diseases , resistant to conventional treatments, such as asthma, arthritis ... inatherys' monoclonal antibodies ina01 and ina02 meet a real medical need. these molecules have demonstrated their effectiveness in preclinical studies and will be developed in patients in advanced stages of their disease, when traditional treatments are no longer effective. our team management founders administrative board coralie belanger ceo and medical director read more pierre launay operational and scientific director read more cécile réal financial and administrative management advisor read more olivier hermine chairman of the scientific council read more pierre launay operational and scientific director read more renato monteiro scientific advisor read more ivan moura scientific advisor read more coralie belanger ceo and medical director read more cécile réal financial and administrative management advisor read more dominique megret board member read more anne bousseau board member read more jacky vonderscher board member read more coralie belanger ceo and medical director × graduated from paris v faculty of medecine and hospital practitioner at necker hospital’s adult hematology service, coralie joined in 2002 the business unit oncology of novartis, france as medical manager of rare tumors/hematology unit. as such, she contributed to the national and international recording and development strategy as well as the medico-marketing strategy of oncology products in close collaboration with regulatory affairs and health authorities. she joined inatherys in 2011. she undertook the challenge+ training program of french management and business school (hec). close pierre launay operational and scientific director × co-founder, in charge of the scientific direction and the product developments. doctor in immunology, inserm research director and team “avenir” director of u699 unit. doctoral student at necker hospital, pierre has more than 17 years of experience in basic research on monoclonal antibodies and their therapeutic implications and has published some of his work in scientific journals such as cell, nature et science. he coordinated several projects on inflammation (nih grant r01, anr-genopath) and cancer (arc) as well as a research program in allergology (foundation for medical research). former instructor at harvard medical school in boston for 6 years, he characterized new therapeutic targets (ion channels) in inflammation. he was also a scientific consultant for 4 years for synta pharmaceuticals biotechnology company located in lexington. as such, he took part in the creation, in 2001, of a research department within the company on ion channels’ agonists for applications in inflammation. he undertook the challenge+ training program of french management and business school (hec). close cécile réal financial and administrative management advisor × board member and consultant in charge of inatherys financial and administrative management. entrepreneur in health/pharmacology, cécile is the ceo and co-founder of endodiag (2011- ). before that, she founded and managed bioprofile (1999-2007), an innovative company developing a biomaterial for orthopedic surgery’s market. she set up a production site, groups of designer surgeons and an international distribution network (europe, us, japan and australia). she also realized several fundraisings and integrated bioprofile to nexa orthopedics company (californian sme) in 2005 before the resale of nexa orthopedics/bioprofile group to tornier group in 2007. she joined ariana pharma company as chief operating officer (2008-2010). in june of 2008, cécile was elected president of adebag (biocluster of grenoble urban area’s health industries) close olivier hermine chairman of the scientific council × co-founder and chairman of the scientific council of inatherys. professor in hematology, olivier is head of hematology department at necker hospital since 2009, foundeur and coordinator of the reference center of mastocytosis (ceremast) since 2007 and assistant director of cnrs umr 8147 unit since 2008. he is a member of ihu scientific council of genetic diseases at necker hospital and assistant director of « club du globule rouge ». he coordinated several projects on lymphoproliferations connected to hepatitis c virus (anr), a research program on mantle cell lymphomas (inca), programs (anr and cancer league) on erythropoeisis regulation. he is the co-founder and member of the scientific committee of ab science, a biotechnology company listed on the paris stock exchange, involved in the development of tyrosine kinase inhibitors. olivier is the author or co-author of 365 publications in renowned international scientific journals. in 1999, he received the “olga saint de la ligue contre le cancer” prize, in 2008 the jean bernard prize and in 2011 the guillaume piel prize of foundation for medical research. national and international referent in the management of hematologic malignancies, he brings to inatherys his expertise in the conception and realization of clinical sudies as well as in the exploitation of results. he will also be involved in scientific communications and multicenter programs of clinical research. close pierre launay operational and scientific director × co-founder, in charge of the scientific direction and the product developments. doctor in immunology, inserm research director and team “avenir” director of u699 unit. doctoral student at necker hospital, pierre has more than 17 years of experience in basic research on monoclonal antibodies and their therapeutic implications and has published some of his work in scientific journals such as cell, n
Informations Whois
Whois est un protocole qui permet d'accéder aux informations d'enregistrement.Vous pouvez atteindre quand le site Web a été enregistré, quand il va expirer, quelles sont les coordonnées du site avec les informations suivantes. En un mot, il comprend ces informations;
Domain Name: inatherys.com
Registry Domain ID: 1563320449_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.1and1.com
Registrar URL: http://1and1.com
Updated Date: 2016-07-24T07:30:04.000Z
Creation Date: 2009-07-23T16:17:24.000Z
Registrar Registration Expiration Date: 2017-07-23T16:17:24.000Z
Registrar: 1&1 Internet SE
Registrar IANA ID: 83
Registrar Abuse Contact Email: abuse@1and1.com
Registrar Abuse Contact Phone: +1.8774612631
Reseller:
Domain Status: clientTransferProhibited https://www.icann.org/epp#clientTransferProhibited
Domain Status: autoRenewPeriod https://www.icann.org/epp#autoRenewPeriod
Registry Registrant ID:
Registrant Name: Pierre Launay
Registrant Organization:
Registrant Street: 16 Rue Henri Huchard
Registrant Street: Faculte de Medecine Xavier Bichat
Registrant City: Paris
Registrant State/Province:
Registrant Postal Code: 75018
Registrant Country: FR
Registrant Phone: +33.157277756
Registrant Phone Ext:
Registrant Fax: +33.157277661
Registrant Fax Ext:
Registrant Email: launaypi@gmail.com
Registry Admin ID:
Admin Name: Pierre Launay
Admin Organization:
Admin Street: 16 Rue Henri Huchard
Admin Street: Faculte de Medecine Xavier Bichat
Admin City: Paris
Admin State/Province:
Admin Postal Code: 75018
Admin Country: FR
Admin Phone: +33.157277756
Admin Phone Ext:
Admin Fax: +33.157277661
Admin Fax Ext:
Admin Email: launaypi@gmail.com
Registry Tech ID:
Tech Name: Hostmaster UNETUN
Tech Organization: 1&1 Internet SARL
Tech Street: 7, place de la Gare
Tech City: Sarreguemines
Tech State/Province:
Tech Postal Code: 57200
Tech Country: FR
Tech Phone: +33.970808911
Tech Phone Ext:
Tech Fax: +33.387959974
Tech Fax Ext:
Tech Email: hostmaster@1and1.fr
Nameserver: ns61.1and1.fr
Nameserver: ns62.1and1.fr
DNSSEC: Unsigned
URL of the ICANN WHOIS Data Problem Reporting System: http://wdprs.internic.net/
>>> Last update of WHOIS database: 2017-05-14T10:28:57Z <<<
For more information on Whois status codes, please visit https://icann.org/epp
REGISTRAR 1&1 INTERNET SE
REFERRER http://registrar.1and1.info
SERVERS
SERVER com.whois-servers.net
ARGS domain =inatherys.com
PORT 43
SERVER whois.1and1.com
ARGS inatherys.com
PORT 43
TYPE domain
RegrInfo
DOMAIN
NAME inatherys.com
NSERVER
NS61.1AND1.FR 217.160.80.170
NS62.1AND1.FR 217.160.81.170
STATUS
clientTransferProhibited https://icann.org/epp#clientTransferProhibited
CHANGED 2016-07-24
CREATED 2009-07-23
EXPIRES 2017-07-23
REGISTERED yes
Go to top
inatherys.com rapport :
Visitez le site